-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Cinda Biopharmaceuticals announced that the glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist IBI362 has been randomly selected among overweight or obese Chinese subjects.
https://doi.
China is the country with the largest number of obese people in the world, and it is showing a gradual upward trend
IBI362 (LY3305677) is an innovative oxyntomodulin compound (OXM3) jointly promoted by Innovent Biopharmaceuticals and Eli Lilly.
The results of clinical studies showed that each dose group of IBI362 improved in waist circumference, body mass index, blood pressure, cholesterol and triglyceride levels, and was well tolerated in overweight or obese Chinese subjects, and had significant weight loss effects.
In the future, it is expected that IBI362 as a multi-target innovative drug in the subsequent phase II clinical studies in overweight/obese subjects will show even more surprising results
Reference materials:
[1]https://mp.
